

# FROM INFLAMMATION TO VITALITY<sup>\*1,2</sup>

TURN TO THE IBD TREATMENT TRIED AND TRUSTED IN TENS OF THOUSANDS OF PATIENTS WORLDWIDE<sup>3</sup>



**Inflectra<sup>®</sup>**  
infliximab

## INFLECTRA<sup>®</sup> (infliximab) TREATMENT CHECKLIST

### What should you take into account before starting INFLECTRA<sup>®</sup> (infliximab)?

Fully review the INFLECTRA<sup>®</sup> (infliximab) Full Prescribing Information, including Important Safety Information, prior to starting treatment.

Additionally, take the following considerations into particular account:

#### ● **Actively monitor patients for infections:**<sup>4</sup>

- Screenings for latent/active tuberculosis and hepatitis B

#### ● **Vaccinate:**<sup>4</sup>

- Bring paediatric patients up to date with all vaccinations prior to initiating treatment if possible

#### ● **Discuss potential health issues with patients:**<sup>4</sup>

- Heart problems
- Lymphoma or any other cancer
- Lung disease or heavy smoking
- Problems that affect the nervous system, such as multiple sclerosis, Guillain-Barre syndrome, or optic neuritis
- Abnormal skin openings
- Imminent operations
- Dental issues, including planned operations or procedures

#### ● **Monitor:**<sup>4</sup>

- The general condition of patients (e.g., symptoms of bacterial or viral infections, fever, ulcers or purulent discharge from fistulas)

### INFLECTRA<sup>®</sup> (infliximab) MUST NOT be given in:<sup>4</sup>

- Cases of tuberculosis, or other severe infections such as sepsis, abscesses and opportunistic infections
- Patients with a history of hypersensitivity to infliximab (or any of its excipients) or other murine proteins

### What should you consider or monitor during INFLECTRA<sup>®</sup> (infliximab) treatment?

#### ● **Consider the long half-life of infliximab when planning certain vaccinations or surgical procedures:**<sup>4</sup>

- Closely monitor patients who require surgery for infections

#### ● **Avoid concurrent administration of INFLECTRA<sup>®</sup> (infliximab) with live vaccines or therapeutic infectious agents such as live attenuated bacteria:**<sup>4</sup>

- Also avoid administration of live vaccines in infants ≤6 months of age who have been exposed to infliximab in utero

\* CT-P13 was designed with comparable efficacy, safety and quality to reference infliximab, to increase the treatment options for your Crohn's disease and ulcerative colitis patients.<sup>5,6</sup> Increasing real-world experience confirms the CT-P13 clinical efficacy and safety profile.<sup>7</sup>

IBD, Inflammatory bowel disease.

1. Geese KB, et al. J Crohns Colitis 2016;10(2):133-40. 2. Jørgensen KK, et al. Lancet 2017;389:2304-16. 3. QuintilesIMS. MIDAS, February 2017. 4. INFLECTRA<sup>®</sup> (infliximab) preparato charakteristikų santrauka 06/2018. 5. European Public Assessment Report: INFLECTRA<sup>™</sup>. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Public\\_assessment\\_report/human/002778/WC500151490.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf). Accessed December 2017. 6. European Medicines Agency. Guidelines on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2012/06/WC500128686.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf). Accessed December 2017. 7. Danese S, et al. J Crohns Colitis 2017;11:26-34.